Choi-Lai Tiong-Yip - Concepedia

Author

Choi-Lai Tiong-Yip

AstraZeneca (United States)

Also Known As

C. Tiong-Yip, Choi-Lai Tiong-Yip, ChoiLai TiongYip

Publications

441

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Novartis (United States)AstraZeneca (United Kingdom)

About

Choi-Lai Tiong-Yip is an author at AstraZeneca (United States) specializing in virology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	402
2	Molecular Biology	5	5	295
3	Immunology	4	4	251
4	Pharmacology	4	4	312
5	Biomolecular Engineering	1	1	20

Choi-Lai Tiong-Yip

Publications

441

Citations

H-Index

Page 1

	Year	Citations
NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon Sue Ma, Joanna E. Boerner, Choi-Lai Tiong-Yip, Antimicrobial Agents and Chemotherapy ImmunologyMolecular BiologyVarious Cyclosporine DerivativesAntiviral DrugImmunotherapy	2006	160
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer George S. Tria, Tinya J. Abrams, Jason R. Baird, Journal of Medicinal Chemistry Oral BioavailabilityBreast OncologyChemoprevention StrategyPharmacotherapyMolecular Pharmacology	2018	123
Characterization of a Respiratory Syncytial Virus L Protein Inhibitor Choi-Lai Tiong-Yip, Lisa Aschenbrenner, Kenneth D. Johnson, Antimicrobial Agents and Chemotherapy Virus StructureViral ReplicationMolecular VirologyMedicineImmunology	2014	59
Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor Hui Xiong, Melinda A. Foulk, Lisa Aschenbrenner, Bioorganic & Medicinal Chemistry Letters Viral ReplicationAntiviral Drug DevelopmentMolecular BiologyVirologyAntiviral Drug	2013	39
Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease Sameer Kawatkar, Moriah M. Gagnon, Valerie Hoesch, Bioorganic & Medicinal Chemistry Letters Virus StructureMedicineImmunologyAntiviral Drug DevelopmentMolecular Biology	2016	20
Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors Choi-Lai Tiong-Yip, Helen Plant, Paul T. Sharpe, Antiviral Research Viral DiagnosticsMedicineHigh-throughput Replicon AssayAntiviral Drug DevelopmentMolecular Biology	2013	17
High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors Helen Plant, Clare Stacey, Choi-Lai Tiong-Yip, SLAS DISCOVERY Molecular Diagnostic TechniquesRespiratory Virus ImmunityRespiratory Syncytial VirusViral DiagnosticsMedicine	2015	12
ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY Bing Li, Joke Snoeck, Yanhua Tang, Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirology	2011	11

Page 1